Isoptin Rr

Verapamil Hydrochloride, the active ingredient in Isoptin Rr, is a calcium channel blocker presented as an oral tablet for oral use. It is employed to manage high blood pressure, chest pain from angina, and certain rapid heart rhythms in adult patients. GNH USA supplies Isoptin Rr as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Isoptin Rr acts on the cardiovascular system by modulating calcium influx, which influences blood pressure and heart rhythm. - Hypertension: lowers systolic and diastolic pressure to reduce cardiovascular risk. - Angina pectoris: decreases myocardial oxygen demand and relieves chest pain. - Supraventricular tachyarrhythmias: slows conduction through the AV node to control rapid heart rates.

Common Side Effects: - Constipation: mild to moderate difficulty passing stool. - Headache: transient pressure sensation. - Dizziness: feeling of light‑headedness, especially on standing. - Flushing: warm, reddened skin. - Peripheral edema: swelling of ankles or feet. - Nausea: upset stomach.

Serious or Rare Side Effects: - Bradycardia: abnormally slow heart rate. - Severe hypotension: marked drop in blood pressure. - Heart block: impaired electrical conduction. - Allergic reaction: rash, itching, swelling, or breathing difficulty. - Hepatic enzyme elevation: abnormal liver function tests.

Before initiating therapy, clinicians should consider several safety measures. - Blood pressure monitoring: ensure adequate control and avoid excessive drops. - Cardiac function assessment: evaluate for existing conduction disorders. - Concomitant beta‑blocker use: adjust doses to prevent excessive bradycardia. - Hepatic impairment: consider dose reduction in patients with liver dysfunction. - Abrupt discontinuation: taper gradually to avoid rebound hypertension. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Verapamil may interact with several medicines, requiring careful management. Major Interactions (Avoid): - Beta‑blockers: risk of profound bradycardia and hypotension. - Digoxin: increased serum levels leading to toxicity. - Diltiazem: additive cardiac conduction slowing. - Quinidine: heightened antiarrhythmic effect. - Strong CYP3A4 inhibitors (e.g., ketoconazole): elevated verapamil concentrations.

Moderate Interactions (Monitor Closely): - Amiodarone: possible increase in verapamil levels. - Statins (especially simvastatin): enhanced risk of myopathy. - Macrolide antibiotics: modest rise in plasma concentration. - Other antihypertensives: additive blood pressure lowering. - NSAIDs: may reduce antihypertensive efficacy.